At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...

Ras-el-hanout is used in couscous, rice, meat and vegetable dishes ...

Suzanne is a content marketer, writer, and fact-checker. She holds a Bachelor of Science in Finance degree from Bridgewater State University and helps develop content strategies. Cash flow statements ...

Daraxonrasib is poised to become the new standard of care for previously treated metastatic pancreatic cancer after detailed results from a Phase III clinical trial were released at the American ...

An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...